Tazemetostat + Nivolumab + Ipilimumab
Phase 1/2RecruitingDevelopment Stage
Atypical Teratoid Rhabdoid Tumor
Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors, Malignant Rhabdoid Tumor (MRT), Rhabdoid Tumor of the Kidney (RTK), Epithelioid Sarcoma, Chordoma
Aug 10, 2023 → Feb 1, 2029
About Tazemetostat + Nivolumab + Ipilimumab
Tazemetostat + Nivolumab + Ipilimumab is a phase 1/2 stage product being developed by Bristol Myers Squibb for Atypical Teratoid Rhabdoid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05407441. Target conditions include Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05407441 | Phase 1/2 | Recruiting |
Competing Products
18 competing products in Atypical Teratoid Rhabdoid Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Pre-clinical | 23 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Iptcaopan 200 mg | Novartis | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Ropeginterferon Alfa-2B | PharmaEssentia | Phase 2 | 51 |
| CCX168 | Amgen | Phase 2 | 51 |
| Cemdisiran | Alnylam Pharmaceuticals | Phase 2 | 49 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 49 |
| Axatilimab + Azacitidine | Incyte | Phase 1/2 | 38 |
| Gemcitabine + Paxalisib | Pacific Biosciences | Phase 2 | 44 |
| Apatinib Mesylate | Brain Biotech | Pre-clinical | 15 |
| azurin-derived cell-penetrating peptide p28 | Brain Biotech | Phase 1 | 25 |